Altimmune's Upcoming Investor Conferences and Strategies

Author: Ryan Hughes Updated: 08-26-2025 07:47 AM

Introduction to Altimmune's Conference Participation

Altimmune, Inc. is a leading biopharmaceutical company focused on developing innovative peptide-based therapeutics tailored for liver and cardiometabolic diseases. The management team recently announced their participation in several prominent investor conferences, providing opportunities for one-on-one meetings with potential investors and stakeholders.

Investor Conferences Overview

Wells Fargo Healthcare Conference

One of the key events is the Wells Fargo Healthcare Conference, set to be held in Boston. This event emphasizes exclusive one-on-one meetings, allowing Altimmune's management to engage directly with investors to discuss future strategies and innovations.

H.C. Wainwright Global Investment Conference

Following the Wells Fargo event, Altimmune will also participate in the H.C. Wainwright Global Investment Conference in New York. This event features a fireside chat scheduled for 8:30 a.m. Eastern Time, offering insights into Altimmune's latest developments. This session will be accessible via webcast, enabling a broader audience to engage with the company.

Morgan Stanley Global Healthcare Conference

Another significant occasion is the Morgan Stanley Global Healthcare Conference. Altimmune's leaders will participate in a fireside chat at 7:45 a.m. Eastern Time, also available through a webcast. This provides an excellent platform for discussing their advancements and the impact of their therapies.

About Altimmune's Innovative Therapies

Altimmune is currently at a late clinical stage in its development of drugs like pemvidutide, which acts as a GLP-1/glucagon dual receptor agonist. This innovative candidate aims to treat conditions such as Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH), Alcohol Use Disorder (AUD), and obesity-related issues. The research focuses on leveraging peptides to enhance treatment efficacy for patients.

Company Leadership and Contact Information

Under the leadership of Greg Weaver, Chief Financial Officer, Altimmune is committed to advancing its clinical pipeline and engaging with investors about long-term strategies. For inquiries, investors and interested parties can reach out to:

Company Contact:

Greg Weaver
Chief Financial Officer
Phone: 240-654-1450
Email: ir@altimmune.com

Investor Contact:

Lee Roth
Burns McClellan
Phone: 646-382-3403
Email: lroth@burnsmc.com

Media Contact:

Jake Robison
Inizio Evoke Comms
Phone: 619-849-5383
Email: jake.robison@inizioevoke.com

Frequently Asked Questions

What is Altimmune's main focus?

Altimmune primarily focuses on developing peptide-based therapeutics for treating liver and cardiometabolic diseases.

When will Altimmune participate in investor conferences?

Altimmune will participate in several investor conferences, including the Wells Fargo Healthcare Conference, the H.C. Wainwright Global Investment Conference, and the Morgan Stanley Global Healthcare Conference.

What therapies is Altimmune developing?

The company is developing pemvidutide, aimed at treating conditions such as MASH and Alcohol Use Disorder.

How can I contact Altimmune for investor inquiries?

Investors can contact Greg Weaver, the CFO, or Lee Roth for investor relations through the provided email addresses.

Is there a webcast available for the conferences?

Yes, each of the conferences will have webcasts available for those unable to attend in person.

About The Author

Hello, my name is Ryan Hughes. I am a financial, economics, and stock market specialist committed to assisting people in negotiating the intricacies of the financial system. Having a great deal of experience and a thorough grasp of market dynamics and economic trends, my area of expertise is converting complex financial ideas into understandable, practical knowledge. By use of my articles and blog entries, I hope to give you the information and assurance you need to make wise financial choices.

I've had the honor of interacting with a wide range of readers as a writer for several financial blogs, from new investors to seasoned market participants. To enable you to reach your financial goals, I want to make finance, economics, and stock market trends understandable and approachable. I appreciate you traveling with me toward success and financial literacy.

Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.